Who are Bevacizumab as MYL-1402O's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intravitreal Aflibercept Injection, Ziv aflibercept, Intravitreal Bevacizumab IVB, Aflibercept Intravitreous Injection, Intravitreal bevacizumab, Ranibizumab and laser.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bevacizumab-as-myl-1402o.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Bevacizumab as MYL-1402O — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bevacizumab as MYL-1402O (Bevacizumab as MYL-1402O) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody; VEGF inhibitor; Antiangiogenic agent. Area: Oncology.

phase 3 Monoclonal antibody; VEGF inhibitor; Antiangiogenic agent VEGF (Vascular Endothelial Growth Factor) Oncology Biologic Live · refreshed every 30 min

Target snapshot

Bevacizumab as MYL-1402O (Bevacizumab as MYL-1402O) — Mylan Pharmaceuticals Inc. MYL-1402O is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bevacizumab as MYL-1402O TARGET	Bevacizumab as MYL-1402O	Mylan Pharmaceuticals Inc	phase 3	Monoclonal antibody; VEGF inhibitor; Antiangiogenic agent	VEGF (Vascular Endothelial Growth Factor)
Intravitreal Aflibercept Injection	Intravitreal Aflibercept Injection	Ophthalmic Consultants of Boston	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Ziv aflibercept	Ziv aflibercept	Marashi Eye Clinic	marketed	VEGF inhibitor / Antiangiogenic agent	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Intravitreal Bevacizumab IVB	Intravitreal Bevacizumab IVB	Khyber Teaching Hospital	marketed	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)
Aflibercept Intravitreous Injection	Aflibercept Intravitreous Injection	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (placental growth factor)
Intravitreal bevacizumab	Intravitreal bevacizumab	University of Sao Paulo	marketed	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)
Ranibizumab and laser	Ranibizumab and laser	Fukushima Medical University	marketed	VEGF inhibitor (monoclonal antibody fragment) combined with laser photocoagulation	VEGF-A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody; VEGF inhibitor; Antiangiogenic agent class)

Mylan Pharmaceuticals Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bevacizumab as MYL-1402O — Competitive Intelligence Brief. https://druglandscape.com/ci/bevacizumab-as-myl-1402o. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab